In vitro inhibition of the classical pathway of human complement by polymyxin B.
Polymyxin B was found to be an inhibitor of the classical pathway of the complement system. The main sites of inhibition were the interaction of EAC14 with C2 and EAC142 with C3. It also inhibited EAC1-9 formation from EAC1-3 and C5-9 though slightly less efficiently. It did not inhibit C3/C5 convertase of the alternative pathway or its formation. The inhibition of the classical pathway was reversible since hemolytic activity was almost completely restored after dialysis.
Asghar
S S
SS
Boot
T
T
van der Helm
H J
HJ
D000818:Animals; D003167:Complement Activation / Q000187:drug effects*; D003175:Complement C2 / Q000172:deficiency / Q000502:physiology; D003169:Complement Inactivator Proteins; D003171:Complement Pathway, Classical / Q000187:drug effects*; D004546:Elapid Venoms / Q000494:pharmacology; D004912:Erythrocytes / Q000276:immunology; D006168:Guinea Pigs; D006801:Humans; D011112:Polymyxin B / Q000494:pharmacology*; D011113:Polymyxins / Q000494:pharmacology*; D011817:Rabbits; D012756:Sheep
D003175:Complement C2; D003169:Complement Inactivator Proteins; D004546:Elapid Venoms; D011113:Polymyxins; C016310:cobra venom factor; D011112:Polymyxin B